Epigenomics AG

General information
Epigenomics AG
Geneststraße 5
10829 Berlin, Berlin

Contact person: Gregory Hamilton, Chief Executive Officer
Company main phone: +49 (30) 243450
Company main fax:  +49 (30) 24345555
Website:  https://www.epigenomics.com
Year founded:1998
Source of foundation:Independent foundation
No. of employees: Worldwide:  36
Corporate description / mission:
Epigenomics AG is a molecular diagnostics company focused on blood-based detection of cancers using the proprietary DNA methylation technology. The company develops and markets blood-based diagnostic products across multiple cancer indications. Epigenomics' lead product, Epi proColon® is a blood-based screening test for the detection of colorectal cancer.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 2004
  • Biotechnology - Therapeutics and Diagnostics
  • Molecular diagnostics
Primary therapeutic areas:
  • Neoplasms / cancer / oncology
Business model:
  • Manufacturer
  • R&D
  • Supplier / Distributor
Customer segments:
  • Consumers (mass market)
  • Hospitals
  • Physicians / doctors
  • Direct (own sales force)
  • Indirect (independent dealer)
Summary Products / Services / Technologies
Description of products:
Epi proColon® – Liquid biopsy test for the detection of colorectal cancer
Epi proLung® – Liquid biopsy test for lung cancer detection
Epi BiSKit
Technology used:
DNA methylation biomarker technology
Financing details
Market cap. / valuation:EUR 6.18M